Browse the toolkit beneath workflows. The mechanism branch runs mechanism -> architecture -> component, while the technique branch runs from high-level approaches down to concrete methods.
15 items matching 1 filter
Mechanism Branch
Layer 1
Mechanisms
Top-level concepts: biophysical action modes such as heterodimerization, photocleavage, or RNA binding.
Layer 2
Architectures
Arrangements that realize or deploy mechanisms, including switches, construct patterns, and delivery strategies.
Layer 3
Components
Low-level parts and sequence-defined elements used inside architectures, including protein domains and RNA elements.
Technique Branch
Layer 1
Approaches
High-level engineering practices such as computational design, directed evolution, sequence verification, and functional assay.
Layer 2
Methods
Concrete methods used to design, build, verify, or characterize engineered systems.
Showing 1-15 of 15
recent developments in the field of theranostic nanoparticles (TNPs) with dual actions of inhibiting HIF-1a and downstream metabolic targets, while facilitating the imaging and treatment of the tumor
the exploration of biomimetic liposomes has revealed their potential in targeted therapy, immune camouflage, immune modulation, gene delivery and vaccine development
Biological nanoparticles, such as exosomes, virus-like particles, and biomimetic nanostructures, possess unique properties that can address these limitations.
It summarizes findings from early clinical and preclinical studies, comparing several carrier types such as ionizable lipid nanoparticles, polymeric nanoparticles, micelles, gold and silica nanostructures, and engineered extracellular vesicles. However, new polymer-based and exosome-inspired carriers are progressing rapidly for repeated and targeted applications.
Hybrid nanocarriers have emerged as a transformative development in modern precision oncology, enabling the co-delivery of gene therapy and immunotherapy agents in a highly targeted manner.
Recent clinical achievements ... have been based on developments in backbone chemistry, nucleoside modifications and targeted delivery including ... lipid nanoparticle (LNP) encapsulation.
A multitude of substances are currently under investigation for the preparation of nanoparticles for drug delivery, varying from biological substances like albumin, gelatine and phospholipids for liposomes
Recent clinical achievements ... have been based on developments in backbone chemistry, nucleoside modifications and targeted delivery including N-acetylgalactosamine (GalNAc) conjugation
Extrahepatic delivery via innovations in delivery that included ligand-targeted LNPs, peptide conjugates and engineered exosomes is surpassing
Platelet membrane-coated nanoparticles, extracellular vesicles, microbubbles, microemulsions, as well as platelet membrane vesicles and their derivatives have shown significant promise for I/RI treatment.
Platelet membrane-coated nanoparticles, extracellular vesicles, microbubbles, microemulsions, as well as platelet membrane vesicles and their derivatives have shown significant promise for I/RI treatment.
Platelet membrane-coated nanoparticles, extracellular vesicles, microbubbles, microemulsions, as well as platelet membrane vesicles and their derivatives have shown significant promise for I/RI treatment.
Platelet membrane-coated nanoparticles, extracellular vesicles, microbubbles, microemulsions, as well as platelet membrane vesicles and their derivatives have shown significant promise for I/RI treatment.
alongside advanced formulations like LNPs and polymeric nanocarriers, exploring their mechanisms of viral inactivation, sensitive detection, and controlled delivery of therapeutics
We discuss technological innovations that have overcome historic challenges related to RNA instability, immunogenicity, and delivery, with particular emphasis on lipid nanoparticle formulations and targeted ligand conjugates.